Dec 14, 2006
PASADENA, CA. – (BusinessWire) – December 14, 2006. Materia, Inc., a catalyst technology company, announced today the non-exclusive licensing of its metathesis platform to Merck & Co, Inc., a global pharmaceutical company, for use in the discovery and development of pharmaceuticals. No financial terms of the agreement were disclosed. Read more
PASADENA, CA. – (BusinessWire) – October 23, 2006. Materia has announced NIH funding for the further development of a metathesis-enabled reagent system for drug discovery.
The program, jointly conducted with Dr. Paul Hanson at the University of Kansas through a National Institutes of Health Small Business Technology Transfer (STTR) grant, will use Materia’s proprietary Ring Opening Metathesis (ROM) catalysts to generate broadly-applicable reagents and matrices for drug development. These tools will be used by pharmaceutical researchers to aid compound design via efficient modification of functional handles, as well as simplifying the resulting compounds’ purification. Read more
PASADENA, CA. – (BusinessWire) – August 16, 2006. Materia announced today recent product development success in its partnership with Lanxess Deutschland GmbH (formerly Bayer Material Science AG) in the field of nitrile rubbers. Read more